Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 6/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11670586 | 0.88 | PMP22 (0.66) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL11670211 | 0.87 | ADRB2 (0.63) | ADRB3PMP22ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL11671078 | 0.86 | PMP22 (0.64) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL11271070 | 0.86 | PMP22 (0.68) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL4761715 | 0.85 | ADRB1 (0.51) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL4880117 | 0.83 | ADRB2 (0.61) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL11670117 | 0.82 | KDM4E (0.64) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL11670188 | 0.80 | ADRB3 (0.67) | ADRB3PMP22ADRB2ADRB1CYP1A2 | |
| SCHEMBL4627149 | 0.80 | ADRB2 (0.79) | PMP22ADRB2ADRB1CYP1A2CYP2D6 | |
| SCHEMBL11671110 | 0.77 | ADRB2 (0.53) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | SOSEI R&D LTD. (GB) | 2008-12-11 | — | — | US | claimed |
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | SOSEI R&D LTD. (GB) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | HRH3, OPRL1, HRH2 | ADRB3 95/4885PMP22 621/4885ADRB2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.